Neofect Co., Ltd. (KOSDAQ:290660)
South Korea · Delayed Price · Currency is KRW 1,296.00
-42.00 (-3.14%)
At close: Mar 27, 2026
Neofect Revenue
In the year 2025, Neofect had annual revenue of 16.05B KRW, down -7.07%. Neofect had revenue of 4.45B in the quarter ending December 31, 2025, a decrease of -12.02%.
Revenue
16.05B
Revenue Growth
-7.07%
P/S Ratio
6.24
Revenue / Employee
281.63M
Employees
57
Market Cap
100.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.05B | -1.22B | -7.07% |
| Dec 31, 2024 | 17.27B | -9.34B | -35.09% |
| Dec 31, 2023 | 26.61B | 412.30M | 1.57% |
| Dec 31, 2022 | 26.20B | 3.04B | 13.14% |
| Dec 31, 2021 | 23.16B | 4.53B | 24.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genoray | 102.75B |
| DRGEM | 102.75B |
| JPI Healthcare | 52.79B |
| L&K Biomed | 38.92B |
| Hironic | 33.18B |
| SELVAS Healthcare | 29.79B |
| Remed | 24.50B |
| Noul Co.,Ltd. | 3.91B |